Amsterdam Institute for Addiction Research and Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Eur Neuropsychopharmacol. 2010 Feb;20(2):69-79. doi: 10.1016/j.euroneuro.2009.11.001. Epub 2009 Dec 3.
Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an alpha4beta2 nAChR partial agonist and an alpha7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.
药物依赖是一种慢性脑部疾病,其特征是反复发作的复发,即使患者有戒烟的意愿。复发是一个主要问题,需要新的药物疗法来预防复发。烟碱型乙酰胆碱受体(nAChR)在尼古丁依赖、酒精消费和线索诱导的可卡因渴望中起着重要作用。已经发现,刺激 nAChR 会改变和调节对维持药物依赖很重要的大脑区域中的细胞放电。维拉唑尼是一种α4β2 nAChR 部分激动剂和α7 nAChR 完全激动剂,已被注册用于治疗尼古丁依赖,可显著减少尼古丁渴望并预防复发。此外,维拉唑尼还可减少大鼠的酒精摄入量。基于对现有文献的回顾,我们假设维拉唑尼在预防除尼古丁依赖以外的药物依赖患者复发方面可能具有作用。